180 likes | 450 Views
Illumina, Inc. .::. a decade of beads .::. .::. a handful of lessons .::. Illumina, Inc. – The Big Picture. So where did the technology and the company come from? And why is it unique? Technology derived from an academic chemistry laboratory
E N D
Illumina, Inc. .::. a decade of beads .::. .::. a handful of lessons .::. Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Illumina, Inc. – The Big Picture • So where did the technology and the company come from? And why is it unique? • Technology derived from an academic chemistry laboratory • What lessons can we as scientists learn from the Illumina story? • Development of Illumina’s technology teaches scientists commercialization lessons of their inventions • What lessons can those in policy-making positions learn from this story? • Case study illustrates the intentions of the Bayh-Dole Act of 1980 Illumina, Inc. - IGSP Talk Deirdre B. Parsons
What is Illumina today? Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Technological Applications • SNP Genotyping • Gene Expression • Proteomics • Drug/pharmaceutical screening • Chemical/odor sensing Illumina, Inc. - IGSP Talk Deirdre B. Parsons
GlaxoSmithKline, PLC ChevronTexaco Energy/Research Genome Quebec Innovation Centre The Wellcome Trust Sanger Institute National Center Biochip Technology Johns Hopkins University Whitehead Institute University of Tokyo Centre National de Genotypage University of Southern California University of California, Los Angeles Genomas, Inc. The Wellcome Trust Sanger Institute Galileo Genomics, Inc. / Genzion Biosciences, Inc. North American Rheumatoid Arthritis Consortium Invitrogen, Inc. National Cancer Institute Max-Planck Institute of Psychiatry PARC Team PharmacoDesign Cancer Research UK: Edinburgh University Colon Cancer Genetics Group; Institute of Cancer Research; Cancer Research UK London Research Institute Aviagen, Inc. North Shore-Long Island Jewish Health System University of Pennsylvania, the Broad Institute, the CARe Consortium SAIC-Frederick, Inc. Center for Inherited Disease Research (CIDR) Shafallah Center deCODE The Children's Hospital of Philadelphia Johnson & Johnson Pharmaceutical R&D, LLC ReaMetrix Massachusetts General Hospital; Harvard Medical School The United States Department of Agriculture (USDA) Agricultural Research Service (ARS), the University of Missouri-Columbia (MU) and the University of Alberta (UA) MicroArray Quality Control (MAQC) project: FDA, NIH, EPA and USDA Duke University Top 5 Pharmaceutical companies Amgen / Brigham & Women's Hospital Erasmus MC The Genome Institute of Singapore Children's Hospital of Eastern Ontario Mayo Clinic Asuragen deCODE National Genome Research Network Golden Helix IntegraGen National Institute of Genomic Medicine (INMEGEN) SNP Genetics Illumina Partnerships Illumina, Inc. - IGSP Talk Deirdre B. Parsons
So where did it all begin? Illumina, Inc. - IGSP Talk Deirdre B. Parsons
David Walt, Ph.D.Department of ChemistryTufts University Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Target Sensor Covalent attachment Single optical fiber to camera for detection to camera for detection Technological Origins to camera for detection Major limitation: ONE sensor per fiber optic cable Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Single optical fiber Bundled optical fiber Technological Development Pointed optical fiber Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Optical fiber with wells… … and BEADS! Images courtesy of David R. Walt, PhD Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Pools of beads Generation of random arrays Binding changes dye color of bead Fluorescent light signals to detector BeadArray Technology Illumina, Inc. - IGSP Talk Deirdre B. Parsons
FastTrack Genotyping Beads in wells 1M SNP BeadChip Pittsburgh Conference HapMap Project Series B financing IPO raises $103 Million Series A financing Series C financing 96 97 98 99 00 01 02 03 04 05 06 07 Illumina founded Spyder acquired Solexa merger nGenetics acquired CyVera acquired Chronology of Key Events Technology Finance Business Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Things to consider • This is a story about a company with unique technology • That technology was developed by a researcher • Hero story • Balance of Open Science Norms and Commercialization • Many factors impacted the success of the researcher, the technology and the company: • Knowledge of IP • Timing • Industrial partnerships • Due diligence on many fronts • Technology transfer Illumina, Inc. - IGSP Talk Deirdre B. Parsons
What does this mean for YOU? • Performing open academic science and commercializing your inventions is possible • Knowledge of intellectual property is the vehicle • Realistic expectations is a requirement Illumina, Inc. - IGSP Talk Deirdre B. Parsons
Center for Genome Ethics, Law & Policy Bob Cook-Deegan, MD Subhashini Chandrasekharan, PhD Master’s Committee Hunt Willard, PhD Fred Dietrich, PhD Fuqua School of Business Ronnie Chatterji, PhD Columbia University – School of Public Policy Bhaven Sampat, PhD Tufts University David Walt, PhD Peggy Newell, Vice Provost Martin Son, OTLIC Nina Green, Director, OTLIC Illumina, Inc. John Stuelpnagel, DVM Todd Dickinson, PhD Maurissa Bornstein BioVenture Investors Marc Goldberg Acknowledgements Illumina, Inc. - IGSP Talk Deirdre B. Parsons
C A G Illumina, Inc. - IGSP Talk Deirdre B. Parsons